Acceleron Pulmonary Arterial Hypertension R&D Day

New York, November 16, 2018

Please join key opinion leaders and the XLRN team to discuss an R&D deep dive for Pulmonary Arterial Hypertension next Friday in NYC.

Friday, November 16, 2018

8:30am - Registration & Breakfast
9:00am - 12:00pm - Presentations

The Maxwell
Great Room 1
541 Lexington Ave, New York

For more information or to RSVP, contact

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Acceleron Pharma Inc [XLRN] US$2,370 MM MCap
The com­pa­nies cont­in­ue to ad­vance mul­ti­ple Ph2 and Ph3 trials for the treat­ment of chron­ic ane­mia in ad­di­tio­n­al pa­tient pop­u­la­tions of MDS and be­ta-tha­lassemia, and in myelo­fi­bro­sis. The com­pany ex­pects to re­port to­p­line re­sults from Ph2 clin­i­cal trials in PAH (so­tater­cept) and CMT (ACE-083) in Q1 2020. [more in­for­ma­tion]